Yeonsook Moon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeonsook Moon has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Chung Hyun Nahm
Inha Univ, Coll Med, Dept Lab Med, Incheon, South Korea
3 shared publications- Hae-Seong Nam
Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea
3 shared publications - Seung Min Kwak
Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea
3 shared publications - Dong Jun Ha
Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea
2 shared publications - Ji Eun Lee
Department of Pediatrics, Inha University College of Medicine, Incheon, Korea
2 shared publications Jin Ju Kim
Departments of Laboratory Medicine, Pediatrics, and Nuclear Medicine, Medical School of Inha University, Incheon, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Respiratory Function in Different Subtypes of Prediabetes and Its Relationship With Insulin Resistance and Hand Grip Strength
Background: Lung function is reduced in patients with diabetes. However, few studies have examined pulmonary function and spirometric patterns in prediabetes (PDM) subtypes. This study investigated the differences in respiratory function among PDM subtypes and their relationship with insulin resistance and muscle strength in patients with PDM. Methods: Data obtained from 2560 participants, including 1480 patients with PDM and 1080 healthy individuals, were evaluated. Spirometric indices, such as forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), FEV exhaled in 6 s (FEV 6 ), peak expiratory flow rate, and percentage of predicted FVC (%pFVC) and FEV 1 (%pFEV 1 ), were measured. Muscle strength was evaluated by measuring hand grip strength (HGS). PDM was categorized into three subtypes: impaired fasting glucose (IFG), hemoglobin A1c (HbA1c)‐defined PDM (A‐PDM), and combined IFG and A‐PDM (GA‐PDM). The homeostasis model assessment of insulin resistance (HOMA‐IR) was used to estimate insulin resistance. Results: Patients with PDM had significantly lower %pFVC and FEV 6 than healthy individuals, with a 1.4‐fold higher prevalence of restrictive spirometric patterns. GA‐PDM was more prevalent in individuals with low FVC than in those with high FVC. However, no significant difference was observed in the prevalence of IFG between the two groups. HOMA‐IR and HbA1c levels were closely correlated with %pFVC and %pFEV 1 . A‐PDM and GA‐PDM increased the risk of low FVC by 1.2‐ and 1.3‐fold, respectively (odds ratios: 1.274, 95% CI, 1.012–1.604, p = 0.039 and 1.311, 95% CI, 1.042–1.648, p = 0.021, respectively). Patients with A‐PDM had significantly lower HGS than those with IFG, particularly in men. After adjusting for potential confounders, HGS was significantly associated with %pFVC and %pFEV 1 values. Conclusion: Respiratory function is more significantly reduced in patients with A‐PDM or GA‐PDM than in those with IFG, particularly in relation to insulin resistance and decreased muscle strength.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessRespiratory Function in Different Subtypes of Prediabetes and Its Relationship With Insulin Resistance and Hand Grip Strength
Background: Lung function is reduced in patients with diabetes. However, few studies have examined pulmonary function and spirometric patterns in prediabetes (PDM) subtypes. This study investigated the differences in respiratory function among PDM subtypes and their relationship with insulin resistance and muscle strength in patients with PDM. Methods: Data obtained from 2560 participants, including 1480 patients with PDM and 1080 healthy individuals, were evaluated. Spirometric indices, such as forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), FEV exhaled in 6 s (FEV 6 ), peak expiratory flow rate, and percentage of predicted FVC (%pFVC) and FEV 1 (%pFEV 1 ), were measured. Muscle strength was evaluated by measuring hand grip strength (HGS). PDM was categorized into three subtypes: impaired fasting glucose (IFG), hemoglobin A1c (HbA1c)‐defined PDM (A‐PDM), and combined IFG and A‐PDM (GA‐PDM). The homeostasis model assessment of insulin resistance (HOMA‐IR) was used to estimate insulin resistance. Results: Patients with PDM had significantly lower %pFVC and FEV 6 than healthy individuals, with a 1.4‐fold higher prevalence of restrictive spirometric patterns. GA‐PDM was more prevalent in individuals with low FVC than in those with high FVC. However, no significant difference was observed in the prevalence of IFG between the two groups. HOMA‐IR and HbA1c levels were closely correlated with %pFVC and %pFEV 1 . A‐PDM and GA‐PDM increased the risk of low FVC by 1.2‐ and 1.3‐fold, respectively (odds ratios: 1.274, 95% CI, 1.012–1.604, p = 0.039 and 1.311, 95% CI, 1.042–1.648, p = 0.021, respectively). Patients with A‐PDM had significantly lower HGS than those with IFG, particularly in men. After adjusting for potential confounders, HGS was significantly associated with %pFVC and %pFEV 1 values. Conclusion: Respiratory function is more significantly reduced in patients with A‐PDM or GA‐PDM than in those with IFG, particularly in relation to insulin resistance and decreased muscle strength.
- Open Access
- 24 April 2024
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2343163
Identification of a novel splice variant in SEC23B gene in a patient with concomitant presence of congenital dyserythropoietic anemia II and Gilbert’s syndrome
Congenital dyserythropoietic anemias (CDAs) comprise a heterogeneous group of genetic disorders of red cell production characterized by ineffective erythropoiesis and dyserythropoiesis. Four major ...
- 24 April 2024
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2343163
Open AccessIdentification of a novel splice variant in SEC23B gene in a patient with concomitant presence of congenital dyserythropoietic anemia II and Gilbert’s syndrome
Congenital dyserythropoietic anemias (CDAs) comprise a heterogeneous group of genetic disorders of red cell production characterized by ineffective erythropoiesis and dyserythropoiesis. Four major ...
- Open Access
- 6 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1521
A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive value in ES-SCLC. We determined the best independent prognostic biomarker among the four complete blood-count-derived inflammatory biomarkers (CBC-IBs). Subsequently, we analyzed the prognostic or predictive value of combining this independent CBC-IB with PD-L1 (SP142) expression. We prospectively assessed the SP142 analyses in tumor samples at diagnosis. Results: All in all, 55 patients with ES-SCLC were classified into four groups according to the systemic immune inflammation index (SII) (low/high) and SP142 (positive/negative). The best survival was observed in the low-SII/ SP142-positive group, whereas the worst survival was observed in the high-SII/SP142-negative group (p = 0.002). The combined SII-SP142 biomarker was better for predicting both survival and disease progression in patients with ES-SCLC. Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC.
- 6 March 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1521
Open AccessA Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive value in ES-SCLC. We determined the best independent prognostic biomarker among the four complete blood-count-derived inflammatory biomarkers (CBC-IBs). Subsequently, we analyzed the prognostic or predictive value of combining this independent CBC-IB with PD-L1 (SP142) expression. We prospectively assessed the SP142 analyses in tumor samples at diagnosis. Results: All in all, 55 patients with ES-SCLC were classified into four groups according to the systemic immune inflammation index (SII) (low/high) and SP142 (positive/negative). The best survival was observed in the low-SII/ SP142-positive group, whereas the worst survival was observed in the high-SII/SP142-negative group (p = 0.002). The combined SII-SP142 biomarker was better for predicting both survival and disease progression in patients with ES-SCLC. Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC.
- Open Access
- 31 December 2021
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 18 (2) , 110-116
A case of follow-up of a patient with 22q11.2 distal deletion syndrome and a review of the literature
- 31 December 2021
- Published by Korean Society of Medical Genetics in Journal of Genetic Medicine
- Vol. 18 (2) , 110-116
Open AccessA case of follow-up of a patient with 22q11.2 distal deletion syndrome and a review of the literature
- Open Access
- 25 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2201
A Preliminary Study on the Prognostic Impact of Neutrophil to Lymphocyte Ratio of the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer
The cumulative results indicate that the neutrophil to lymphocyte ratio of peripheral blood (pbNLR) is a useful prognostic factor in patients with various cancers. In contrast to peripheral blood, the bronchoalveolar lavage (BAL) fluid is in direct contact with the lung lesion. However, no study has reported on the clinical utility of the NLR of BAL fluid (bNLR) for patients with lung cancer. To investigate the clinical utility of the bNLR as a prognostic factor in patients with lung cancer, we conducted a retrospective review of the prospectively collected data. A total of 45 patients were classified into high bNLR (n = 29) and low bNLR (n = 16) groups. A high pbNLR and high bNLR were associated with a shorter overall survival (p < 0.001 and p = 0.011, respectively). A multivariable analysis confirmed that ECOG PS (p = 0.023), M stage (p = 0.035), pbNLR (p = 0.008), and bNLR (p = 0.0160) were independent predictors of overall survival. Similar to the pbNLR, a high bNLR value was associated with a poor prognosis in patients with lung cancer. Although further studies are required to apply our results clinically, this is the first study to show the clinical value of the bNLR in patients with lung cancer.
- 25 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2201
Open AccessA Preliminary Study on the Prognostic Impact of Neutrophil to Lymphocyte Ratio of the Bronchoalveolar Lavage Fluid in Patients with Lung Cancer
The cumulative results indicate that the neutrophil to lymphocyte ratio of peripheral blood (pbNLR) is a useful prognostic factor in patients with various cancers. In contrast to peripheral blood, the bronchoalveolar lavage (BAL) fluid is in direct contact with the lung lesion. However, no study has reported on the clinical utility of the NLR of BAL fluid (bNLR) for patients with lung cancer. To investigate the clinical utility of the bNLR as a prognostic factor in patients with lung cancer, we conducted a retrospective review of the prospectively collected data. A total of 45 patients were classified into high bNLR (n = 29) and low bNLR (n = 16) groups. A high pbNLR and high bNLR were associated with a shorter overall survival (p < 0.001 and p = 0.011, respectively). A multivariable analysis confirmed that ECOG PS (p = 0.023), M stage (p = 0.035), pbNLR (p = 0.008), and bNLR (p = 0.0160) were independent predictors of overall survival. Similar to the pbNLR, a high bNLR value was associated with a poor prognosis in patients with lung cancer. Although further studies are required to apply our results clinically, this is the first study to show the clinical value of the bNLR in patients with lung cancer.
- 1 January 2021
- Vol. 51 (1) , 136-139
A Novel de novo Mutation in ANK1 Gene Identified through Targeted Next-Generation Sequencing in a Neonate with Hereditary Spherocytosis
Hereditary spherocytosis (HS) is a congenital disorder of the red blood cell membrane and is characterized by hemolytic anemia, variable jaundice, and splenomegaly. In neonates, the diagnosis of HS can be difficult in the absence of family history. Herein, we describe clinical and molecular genetic findings in a Korean neonate with HS. A one-month-old girl presented with severe anemia and jaundice. Spherocytes were frequently observed on peripheral blood smear, but the erythrocyte osmotic fragility test result was normal. Targeted next-generation sequencing (NGS) revealed the patient was heterozygous for a novel frameshift mutation, c.191_194del (p.Leu64Argfs*7), in exon 3 of ANK1 gene. Family study was performed by direct sequencing, and neither of her parents carried this mutation. The patient also harbored the UGT1A1*6 allele. To the best of our knowledge, this ANK1 mutation identified by targeted NGS has not been reported previously.
- 1 January 2021
- Vol. 51 (1) , 136-139
A Novel de novo Mutation in ANK1 Gene Identified through Targeted Next-Generation Sequencing in a Neonate with Hereditary Spherocytosis
Hereditary spherocytosis (HS) is a congenital disorder of the red blood cell membrane and is characterized by hemolytic anemia, variable jaundice, and splenomegaly. In neonates, the diagnosis of HS can be difficult in the absence of family history. Herein, we describe clinical and molecular genetic findings in a Korean neonate with HS. A one-month-old girl presented with severe anemia and jaundice. Spherocytes were frequently observed on peripheral blood smear, but the erythrocyte osmotic fragility test result was normal. Targeted next-generation sequencing (NGS) revealed the patient was heterozygous for a novel frameshift mutation, c.191_194del (p.Leu64Argfs*7), in exon 3 of ANK1 gene. Family study was performed by direct sequencing, and neither of her parents carried this mutation. The patient also harbored the UGT1A1*6 allele. To the best of our knowledge, this ANK1 mutation identified by targeted NGS has not been reported previously.
- Open Access
- 22 August 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-8
Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
- 22 August 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-8
Open AccessPrognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients
- Open Access
- 31 March 2014
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Laboratory Medicine and Quality Assurance
- Vol. 36 (1) , 48-53
Usefulness of Serum IGF-I and IGFBP-3 Levels in Children with Short Stature
- 31 March 2014
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Laboratory Medicine and Quality Assurance
- Vol. 36 (1) , 48-53
Open AccessUsefulness of Serum IGF-I and IGFBP-3 Levels in Children with Short Stature
- Open Access
- 1 January 2014
- Published by Korean Association of Urogenital Tract Infection and Inflammation in The Korean Journal of Urogenital Tract Infection and Inflammation
- Vol. 9 (1) , 50-52
Altered Mentality Patient with Emphysematous Pyelonephritis Disclosed by Abdominal Computed Tomography
Han SB, et al. Korean J Urogenit Tract Infect Inflamm. 2014 Apr;9(1):50-52. http://dx.doi.org/10.14777/kjutii.2014.9.1.50
- 1 January 2014
- Published by Korean Association of Urogenital Tract Infection and Inflammation in The Korean Journal of Urogenital Tract Infection and Inflammation
- Vol. 9 (1) , 50-52
Open AccessAltered Mentality Patient with Emphysematous Pyelonephritis Disclosed by Abdominal Computed Tomography
Han SB, et al. Korean J Urogenit Tract Infect Inflamm. 2014 Apr;9(1):50-52. http://dx.doi.org/10.14777/kjutii.2014.9.1.50
- Open Access
- 1 August 2006
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 26 (4) , 246-248
Chronic Myelogenous Leukemia with a Variant Philadelphia Translocation: t(11;22)(q25;q11.2)
Kim HS, et al. Korean J Lab Med. 2006 Aug;26(4):246-248. https://doi.org/10.3343/kjlm.2006.26.4.246
- 1 August 2006
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 26 (4) , 246-248
Open AccessChronic Myelogenous Leukemia with a Variant Philadelphia Translocation: t(11;22)(q25;q11.2)
Kim HS, et al. Korean J Lab Med. 2006 Aug;26(4):246-248. https://doi.org/10.3343/kjlm.2006.26.4.246